Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinomaC.S. Chai,C.K. Liam, O. Po Lin,Y.K. Pang, G.F. Ho,A. Alip,C.K. Wong, M.E. Poh,J.L. TanANNALS OF ONCOLOGY（2019）引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
